Calcium Channel Blockers for Hypertension and Angina Management

Introduction to Calcium Channel Blockers

The American Heart Association recommends amlodipine as the best calcium channel blocker for hypertension and angina based on the strongest evidence from major cardiovascular outcome trials, demonstrating equivalent or superior blood pressure reduction and cardiovascular event prevention compared to other antihypertensive classes 1, 2

The American College of Cardiology suggests that amlodipine is the preferred dihydropyridine calcium channel blocker, demonstrating equivalent cardiovascular outcomes to thiazide diuretics and ACE inhibitors in ALLHAT, with no significant differences in fatal CAD, nonfatal MI, combined CAD outcomes, or all-cause mortality 2
The European Society of Cardiology recommends that long-acting dihydropyridines are preferred over nondihydropyridines when combining with beta-blockers to avoid excessive bradycardia or heart block 3, 2

The American Heart Association suggests that nifedipine should be dosed at 120-240 mg daily, using long-acting formulations only 4
The European Respiratory Review recommends that diltiazem should be dosed at 240-720 mg daily 4

The American College of Cardiology recommends that amlodipine is first-line for combined hypertension and angina, reducing myocardial oxygen demand by decreasing peripheral vascular resistance and lowering BP 1, 2
The European Society of Cardiology suggests that CCBs are the treatment of choice for vasospastic angina, with amlodipine blocking coronary artery constriction and restoring blood flow in response to various vasoconstrictive stimuli 5

The American Heart Association warns that combining nondihydropyridines with beta-blockers may cause bradycardia and AV block 3, 2
The European Society of Cardiology recommends that caution should be exercised when lowering diastolic BP below 60 mm Hg in patients with diabetes or age >60 years, as this may worsen myocardial ischemia 3, 2

The American College of Cardiology recommends a target BP <130/80 mm Hg in patients with diabetes, chronic renal disease, CAD, or 10-year Framingham risk ≥10% 1
The European Society of Cardiology suggests that most patients require 2 or more drugs to reach goal, and when BP is >20/10 mm Hg above goal, initiate two drugs from outset 1

The American Heart Association recommends that amlodipine combines effectively with ACE inhibitors or ARBs, reducing edema and improving BP control 2
The European Society of Cardiology suggests that amlodipine also combines effectively with thiazide diuretics, using complementary mechanisms 2
The American College of Cardiology recommends that when combining amlodipine with beta-blockers, a long-acting dihydropyridine should be used, not a nondihydropyridine 3, 2

Calcium channel blockers (CCBs) inhibit the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle cells by blocking L-type calcium channels, reducing intracellular calcium availability for muscle contraction 6, 7
This calcium channel inhibition leads to arterial vasodilation, decreased peripheral vascular resistance, and reduced blood pressure 8, 9
The blockade of calcium influx affects both myocardial and vascular smooth muscle contraction to varying degrees depending on the specific agent 10, 11

Dihydropyridines (DHP) have high selectivity for vascular L-type calcium channels and produce pronounced coronary and systemic vasodilation 6, 12
Dihydropyridines exert antianginal effects by reducing oxygen demand and improving coronary dilation 6
Non-dihydropyridines have less selective effects on vasculature and more pronounced effects on myocardial contractility 6
Non-dihydropyridines reduce oxygen demand through reductions in afterload, heart rate, and myocardial contractility 6, 10

All CCBs have similar antianginal efficacy compared to other antianginal drugs 6
Dihydropyridines reduce oxygen demand through decreased afterload 6
Non-dihydropyridines provide additional benefit through heart rate reduction 6
CCBs do not improve survival in patients with chronic stable angina with or without myocardial infarction 6
Leg edema is a common side effect of all CCBs 6
Diltiazem and verapamil should not be combined with ivabradine due to risk of severe bradycardia 6
Rapid-release, short-acting dihydropyridines should be avoided without concomitant beta-blockade due to increased adverse potential 10, 11
Verapamil and diltiazem should be avoided in patients with pulmonary edema or severe LV dysfunction 10, 11